The American Society of Clinical Oncology (ASCO) has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 (177Lu-PSMA-617) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In 2014, ASCO published a guideline on systemic therapy for patients with mCRPC. The guideline was revised in 2022 to include updated guidance on the use of 177Lu-PSMA-617. ...
Prostate Cancer
Advertisement
Latest News
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
Enzalutamide plus leuprolide and enzalutamide monotherapy resulted in significantly MFS and a longer time to PSA progression.
Clarity announced the second phase of the SECuRE trial's third cohort has commenced, as has the phase 3 CLARIFY trial.
Drs. George and Wallis discuss applications and counseling patients on focal therapy, as well as post-treatment follow-up.
Enzalutamide plus leuprolide acetate and enzalutamide alone caused delayed MFS when compared with placebo plus leuprolide.
Advertisement
Conference Coverage
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.
Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Advertisement
Trending
The authors said that “PDEARGs are valuable prognostic predictors and potential therapeutic targets” for patients with ...
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Advertisement
